SEC Form 4 · accession 0001209191-16-106161
ACORDA THERAPEUTICS INC · ACOR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Blight
Officer — Chief Scientific Officer
Period of report
Mar 2, 2016
Accepted (ET)
Mar 4, 2016 · 5:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001008848
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F1 | $35.53 | Mar 2, 2016 | A | 20,300 | A | — | Mar 2, 2026 | Common Stock | 20,300 | 20,300 | D |
Explanation of responses
- F1The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2016 with the first quarterly installment vesting on April 1, 2016.